Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2

Journal of Immunology

Volumn 175, Issue 10, 2005, Pages 6465-6472

  Visintin, Alberto ^a   Halmen, Kristen A ^a   Latz, Eicke ^a   Monks, Brian G ^a   Golenbock, Douglas T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMICAL COMPOUND; E 5564; ENDOTOXIN; ER 112022; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LIPID A DERIVATIVE; MONOMER; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 IMMUNOGLOBULIN FC FRAGMENT HYBRID PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTOXIN DETECTION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; NORMAL HUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN TARGETING; RECEPTOR BINDING; SERUM; SIGNAL TRANSDUCTION;

EID: 27744516113     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.10.6465     Document Type: Article

References (38)

1. Bell, J. K., G. E. Mullen, C. A. Leifer, A. Mazzoni, D. R. Davies, and D. M. Segal. 2003. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol. 24: 528-533.
2. Weber, A. N., S. Tauszig-Delamasure, J. A. Hoffmann, E. Lelievre, H. Gascan, K. P. Ray, M. A. Morse, J. L. Imler, and N. J. Gay. 2003. Binding of the Drosophila cytokine spatzle to Toll is direct and establishes signaling. Nat. Immunol. 4: 794-800.
3. Saitoh, S., S. Akashi, T. Yamada, N. Tanimura, M. Kobayashi, K. Konno, F. Matsumoto, K. Fukase, S. Kusumoto, Y. Nagai, et al. 2004. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int. Immunol 16: 961-969.
4. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
5. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189: 1777-1782.
6. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. Kitamura, A. Kosugi, M. Kimoto, and K. Miyake. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol, 3: 667-672.
7. Schromm, A. B., E. Lien, P. Henneke, J. C. Chow, A. Yoshimura, H. Heine, E. Latz, B. G. Monks, D. A. Schwartz, K. Miyake, and D. T. Golenbock. 2001. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J. Exp. Med. 194: 79-88.
8. Viriyakosol, S., P. S. Tobias, R. L. Kitchens, and T. N. Kirkland. 2001. MD-2 binds to bacterial lipopolysaccharide. J. Biol. Chem, 276: 38044-38051.
9. Visintin, A., E. Latz, B. G. Monks, T. Espevik, and D. T. Golenbock. 2003. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 278: 48313-48320.
10. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, T. Espevik, and D. T. Golenbock. 2003. The LPS receptor generates inflammatory signals from the cell surface. J. Endotoxin Res. 9: 375-380.
11. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277: 47834-47843.
12. Akashi, S., S. Saitoh, Y. Wakabayashi, T. Kikuchi, N. Takamura, Y. Nagai, Y. Kusumoto, K. Fukase, S. Kusumoto, Y. Adachi, et al. 2003. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198: 1035-1042.
13. Inohara, N., and G. Nunez. 2002. ML: a conserved domain involved in innate immunity and lipid metabolism. Trends Biochem. Sci. 27: 219-221.
14. Gangloff, M., and N. J. Gay. 2004. MD-2: the Toll 'gatekeeper' in endotoxin signalling. Trends Biochem, Sci. 29: 294-300.
15. Gruber, A., M. Mancek, H. Wagner, C. J. Kirschning, and R. Jerala. 2004. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J. Biol. Chem. 279: 28475-28482.
16. Mullen, G. E., M. N. Kennedy, A. Visintin, A. Mazzoni, C. A. Leifer, D. R. Davies, and D. M. Segal. 2003. The role of disulfide bonds in the assembly and function of MD-2. Proc. Natl Acad. Sci. USA 100: 3919-3924.
17. Visintin, A., A. Mazzoni, J. A. Spitzer, and D. M. Segal. 2001. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc. Natl. Acad. Sci. USA 98: 12156-12161.
18. Re, F., and J. L. Strominger. 2002. Monomeric recombinant MD-2 binds TLR4 tightly and confers LPS responsiveness. J. Biol. Chem. 277: 23427-23432.
19. Gioannini, T. L., A. Teghanemt, D. Zhang, N. P. Coussens, W. Dockstader, S. Ramaswamy, and J. P. Weiss. 2004. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc. Natl. Acad. Sci. USA 101: 4186-4191.
20. Kennedy, M. N., G. E. Mullen, C. A. Leifer, C. Lee, A. Mazzoni, K. N. Dileepan, and D. M. Segal. 2004. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J. Biol. Chem. 279: 34698-34704.
21. Jack, R. S., X. Fan, M. Bernheiden, G. Rune, M. Ehlers, A. Weber, G. Kirsch, R. Mentel, B. Furll, M. Freudenberg, et al. 1997. Lipopolysaccharide- binding protein is required to combat a murine Gram-negative bacterial infection. Nature 389: 742-745.
22. Wurfel, M. M., B. G. Monks, R. R. Ingalls, R. L. Dedrick, R. Delude, D. Zhou, N. Lamping, R. R. Schumann, R. Thieringer, M. J. Fenton, et al. 1997. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J. Exp. Med. 186: 2051-2056.
23. Perera, P. Y., S. N. Vogel, G. R. Detore, A. Haziot, and S. M. Goyert. 1997. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J. Immunol. 158: 4422-4429.
24. Wang, R. F., X. Wang, S. L. Johnston, G. Zeng, P. F. Robbins, and S. A. Rosenberg. 1998. Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res. 58: 3519-3525.
25. Mullarkey, M., J. R. Rose, J. Bristol, T. Kawata, A. Kimura, S. Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W. J. Christ, and D. P. Rossignol. 2003. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304: 1093-1102.
26. Lien, E., J. C. Chow, L. D. Hawkins, P. D. McGuinness, K. Miyake, T. Espevik, F. Gusovsky, and D. T. Golenbock. 2001. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/Toll-like receptor 4 signaling pathway. J. Biol Chem. 276: 1873-1880.
27. Fitzgerald, K. A., D. C. Rowe, B. J. Barnes, D. R. Caffrey, A. Visintin, E. Latz, B. Monks, P. M. Pitha, and D. T. Golenbock. 2003. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198: 1043-1055.
28. Triantafilou, M., K. Brandenburg, S. Kusumoto, K. Fukase, A. Mackie, U. Seydel, and K. Triantafilou. 2004. Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem. J. 381: 527-536.
29. Pfeiffer, A., A. Bottcher, E. Orso, M. Kapinsky, P. Nagy, A. Bodnar, I. Spreitzer, G. Liebisch, W. Drobnik, K. Gempel, et al. 2001. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur. J. Immunol. 31: 3153-3164.
30. Seid, R. C., Jr., and J. C. Sadoff. 1981. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates. J. Biol. Chem. 256: 7305-7310.
31. von Eschen, K. B., and J. A. Rudbach. 1976. Antibody responses of mice to alkaline detoxified lipopolysaccharide. J. Immunol. 116: 8-11.
32. Lien, E., T. K. Means, H. Heine, A. Yoshimura, S. Kusumoto, K. Fukase, M. J. Fenton, M. Oikawa, N. Qureshi, B. Monks, R. W. Finberg, R. R. Ingalls, and D. T. Golenbock. 2000. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105: 497-504.
33. Poltorak, A., P. Ricciardi-Castagnoli, S. Citterio, and B. Beutler. 2000. Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc. Natl. Acad. Sci. USA 97: 2163-2167.
34. Steeghs, L., R. den Hartog, A. den Boer, B. Zomer, P. Roholl, and P. van der Ley. 1998. Meningitis bacterium is viable without endotoxin. Nature 392: 449-450.
35. Somerville, J. E., Jr., L. Cassiano, B. Bainbridge, M. D. Cunningham, and R. P. Darveau. 1996. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Invest. 97: 359-365.
36. Hyakushima, N., H. Mitsuzawa, C. Nishitani, H. Sano, K. Kuronuma, M. Konishi, T. Himi, K. Miyake, and Y. Kuroki. 2004. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J. Immunol. 173: 6949-6954.
37. Pugin, J., S. Stern-Voeffray, B. Daubeuf, M. A. Matthay, G. Elson, and I. Dunn-Siegrist. 2004. Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 104: 4071-4079.
38. Brennan, C. A., and K. V. Anderson. 2004. Drosophila: the genetics of innate immune recognition and response. Annu. Rev. Immunol. 22: 457-483.